US 12,410,293 B2
Systems and methods relating to medical applications of inverse thermosensitive polymer foam formulations
Ross I. Donaldson, Lawndale, CA (US); Jonathan Armstrong, Inglewood, CA (US); Oliver Buchanan, Inglewood, CA (US); John Cambridge, Inglewood, CA (US); Timothy Fisher, Lawndale, CA (US); and Nely Cristerna, Lawndale, CA (US)
Assigned to Critical Innovations LLC, Lawndale, CA (US)
Filed by Critical Innovations LLC, Lawndale, CA (US)
Filed on Oct. 12, 2023, as Appl. No. 18/485,800.
Claims priority of provisional application 63/423,308, filed on Nov. 7, 2022.
Prior Publication US 2024/0158596 A1, May 16, 2024
Int. Cl. C08J 9/14 (2006.01); A61L 26/00 (2006.01)
CPC C08J 9/146 (2013.01) [A61L 26/0019 (2013.01); A61L 26/0076 (2013.01); A61L 26/0085 (2013.01); C08J 2371/02 (2013.01)] 15 Claims
 
1. A pressurized inverse thermosensitive polymer foam formulation configured to be stored in a valved container designed to maintain the formulation under pressure and dispense the formulation upon opening a valve of the valved container, the formulation comprising:
an aqueous solution of a copolymer of ethylene oxide and propylene oxide, wherein the aqueous solution is configured to undergo a reverse phase change from a liquid to a gel;
one or more antibiotics, the one or more antibiotics including vancomycin at a concentration between about 0.1% w/w/to about 6.0% w/w;
a preservative;
a pH adjuster; and
an expanding component that is a liquified hydrofluorocarbon gas, wherein
the formulation comprises a stable and macroscopically homogenous solution,
the formulation is configured to be deployed from the container such that the liquified hydrofluorocarbon gas causes the formulation to foam after the formulation is dispensed from the container,
the formulation is configured to be applied topically, and
the formulation is configured to initially be deployed from the container at a lower viscosity to spread more easily and becomes more viscous upon contact with the body.